Cite this: TNF Signaling Inhibition in the CNS: Implications for Normal Brain Function and Neurodegenerative Disease - Medscape - Oct 17, 2008.

Rakovina will present two abstracts at the meeting, the first: Discovery of novel PARP1-selective inhibitors for treatment of brain tumors using artificial intelligence , explores the use of ...

About A-005 A-005 is a potential first-in-class CNS-penetrant allosteric TYK2 inhibitor being developed for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple scle ...

Synnovation’s other clinical stage program, SNV1521, is a potentially best-in-class potent, selective and CNS penetrant PARP1 inhibitor currently in Phase I. For more information, please visit ...